Gilead Sciences (GILD) Rating Increased to Hold at BidaskClub

Gilead Sciences (NASDAQ:GILD) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

Several other equities research analysts have also commented on GILD. Wells Fargo & Co upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $79.02 to $96.00 in a report on Tuesday. Mizuho reaffirmed a “buy” rating on shares of Gilead Sciences in a research report on Friday, September 29th. BMO Capital Markets reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, January 3rd. Credit Suisse Group set a $80.00 price objective on shares of Gilead Sciences and gave the stock a “hold” rating in a research report on Wednesday, January 3rd. Finally, Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Thursday, October 19th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eighteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $85.53.

Gilead Sciences (NASDAQ:GILD) traded down $0.58 during trading hours on Tuesday, hitting $81.16. 1,964,220 shares of the stock traded hands, compared to its average volume of 8,682,300. Gilead Sciences has a twelve month low of $63.76 and a twelve month high of $86.27. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. The company has a market cap of $105,920.00, a price-to-earnings ratio of 9.23, a P/E/G ratio of -1.71 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. During the same quarter in the previous year, the business posted $2.75 EPS. The company’s quarterly revenue was down 13.2% compared to the same quarter last year. sell-side analysts expect that Gilead Sciences will post 8.53 EPS for the current fiscal year.

In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the sale, the executive vice president now owns 77,363 shares of the company’s stock, valued at approximately $5,788,299.66. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $79.00, for a total transaction of $2,370,000.00. Following the sale, the executive vice president now directly owns 57,114 shares in the company, valued at approximately $4,512,006. The disclosure for this sale can be found here. In the last three months, insiders have sold 491,666 shares of company stock worth $36,442,567. 1.30% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in the business. ANTIPODES PARTNERS Ltd boosted its holdings in shares of Gilead Sciences by 40.6% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,796,482 shares of the biopharmaceutical company’s stock valued at $128,700,000 after acquiring an additional 518,890 shares during the last quarter. Charter Trust Co. boosted its holdings in shares of Gilead Sciences by 42.7% in the 4th quarter. Charter Trust Co. now owns 14,807 shares of the biopharmaceutical company’s stock valued at $1,060,000 after acquiring an additional 4,433 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in shares of Gilead Sciences by 4.1% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 5,160,497 shares of the biopharmaceutical company’s stock valued at $369,699,000 after acquiring an additional 201,109 shares during the last quarter. Coastline Trust Co boosted its holdings in shares of Gilead Sciences by 23.8% in the 4th quarter. Coastline Trust Co now owns 11,125 shares of the biopharmaceutical company’s stock valued at $797,000 after acquiring an additional 2,140 shares during the last quarter. Finally, Sippican Capital Advisors boosted its holdings in shares of Gilead Sciences by 11.9% in the 4th quarter. Sippican Capital Advisors now owns 20,703 shares of the biopharmaceutical company’s stock valued at $1,483,000 after acquiring an additional 2,204 shares during the last quarter. 75.95% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This story was originally reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.truebluetribune.com/2018/01/18/gilead-sciences-gild-rating-increased-to-hold-at-bidaskclub.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply